- Home
- XPEL vs ELVN Comparison
XPEL vs ELVN Comparison
Compare XPEL & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPEL | ELVN |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.8B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | XPEL | ELVN |
|---|---|---|
| Price | $37.95 | $27.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $41.00 |
| AVG Volume (30 Days) | 252.5K | ★ 606.7K |
| Earning Date | 01-01-0001 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.12 | 3.17 |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $476,200,000.00 | N/A |
| Revenue This Year | $12.64 | N/A |
| Revenue Next Year | $11.98 | $40.06 |
| P/E Ratio | $20.66 | ★ N/A |
| Revenue Growth | ★ 13.27 | N/A |
| 52 Week Low | $24.27 | $13.30 |
| 52 Week High | $55.91 | $30.98 |
Technical Indicators
Market Signals| Indicator | XPEL | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 21.99 | 46.76 |
| Support Level | $35.10 | $18.89 |
| Resistance Level | $55.36 | $29.63 |
| Average True Range (ATR) | 2.05 | 1.59 |
| MACD | -0.66 | -0.25 |
| Stochastic Oscillator | 4.72 | 0.54 |
Price Performance
Historical ComparisonAbout XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.